Monitoring After Intracervical Dinoprostone Gel 0.5 mg (Prepidil) — Clinical Guidelines

Background

Pre-Administration Baseline Assessment

Immediate Post-Administration Monitoring (First 30–60 Minutes)

• Continuous CTG for at least 30 minutes after each dose — this is the period of peak prostaglandin absorption and highest risk of uterotonic effect.
• Patient should remain recumbent or semi-recumbent for 15–30 minutes after insertion to prevent gel displacement.
• Monitor for:
  • Early uterine contractions
  • Signs of hypersensitivity (nausea, vomiting, diarrhoea, flushing)
  • Maternal hypotension (transient vasodilation is possible)

Ongoing Monitoring Protocol

Fetal Surveillance

• Any non-reassuring CTG feature (late decelerations, prolonged deceleration, reduced variability, bradycardia) requires immediate clinical review and possible tocolysis.

Uterine Activity Monitoring

• Assess frequency, duration, and strength of contractions every 30 minutes.
• Normal: ≤5 contractions per 10-minute period.
• Tachysystole: >5 contractions in 10 minutes over two consecutive 10-minute windows.
• Hyperstimulation: tachysystole with non-reassuring fetal heart rate changes, or uterine hypertonus (single contraction lasting >2 minutes).

Repeat Dosing Criteria

• A second dose of 0.5 mg may be given after 6 hours if:
  • No labour has established
  • No uterine hyperstimulation
  • CTG remains reassuring
  • Bishop score has not adequately improved
• Maximum cumulative dose: 1.5 mg (3 doses) in 24 hours
• Do not re-dose if:
  • Regular uterine contractions are present
  • CTG is non-reassuring
  • Membranes have ruptured

Oxytocin After Dinoprostone

• Wait at least 6 hours after the last dose of intracervical dinoprostone before commencing oxytocin infusion (NICE CG70, Prepidil SPC).
• This interval reduces the risk of cumulative uterotonic effect and hyperstimulation.
• If using vaginal dinoprostone (PV PGE₂ tablet or Cervidil/Propess pessary), the interval before oxytocin is 30 minutes to 1 hour — but for the intracervical gel, 6 hours is required.

Management of Complications

Uterine Hyperstimulation / Tachysystole with FHR Changes

1. Remove stimulus — intracervical gel cannot be physically removed, unlike the Cervidil retrieval system.
2. Reposition the patient (left lateral).
3. IV fluid bolus (500 mL crystalloid).
4. Stop oxytocin if running.
5. Tocolysis: Terbutaline 0.25 mg SC (or salbutamol IV per local protocol) — inhibits uterine activity.
6. Supplemental oxygen (though evidence for maternal O₂ benefit is limited; use per local protocol).
7. If FHR does not recover → urgent obstetric review, consider emergency delivery.

Maternal Side Effects to Monitor

Documentation Requirements

• Time of gel insertion and Bishop score at insertion
• CTG findings at baseline, 30 min, and ongoing
• Uterine contraction frequency at each assessment
• Maternal vitals at each assessment
• Time of any repeat dosing
• Any adverse events and actions taken

Special Considerations

Summary Algorithm

Baseline CTG (20 min) → Bishop score → Insert dinoprostone 0.5 mg intracervically
        ↓
Patient recumbent 15–30 min
        ↓
Continuous CTG × 30 min minimum
        ↓
Reassuring?  ──NO──→ Immediate review / tocolysis / escalate
    │
   YES
    ↓
Hourly maternal vitals + contraction assessment
Continuous CTG once contractions establish
        ↓
Reassess at 6 hours:
  - Labour established? → Ongoing CTG in labour
  - No labour + no hyperstimulation? → Consider repeat dose (max 3 doses/24h)
        ↓
Oxytocin only after ≥6 hours from last dose if needed

• NICE Clinical Guideline CG70: Induction of Labour (updated 2021)
• ACOG Practice Bulletin No. 107/No. 138: Induction of Labor
• WHO Recommendations for Induction of Labour (2011)
• Prepidil (dinoprostone 0.5 mg) Summary of Product Characteristics
• RCOG Green-top Guideline No. 9: Tocolysis for Women in Preterm Labour